• Abbott received FDA approval and CE Mark for its UltiSynq defibrillation lead, securing regulatory clearance in the U.S. and EU.
• The lead delivers conduction system pacing and defibrillation therapy for patients requiring both treatments.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abbott Laboratories published the original content used to generate this news brief on November 10, 2026, and is solely responsible for the information contained therein.